I believe an interim analysis is just that, an ana
Post# of 145755
This will include evaluation of the primary and secondary endpoints. Data is sent to Amarex for analysis and then to Cytodyn.
The DSMC (data safety monitoring committee) is separate from Amarex and Cytodyn, having authority to stop the trial due to patient risk. This analysis was completed at 149 patients and trial continued.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)